Bio industry statistics connect the science-to-market pipeline: R&D intensity, clinical success rates, and the time it takes for drugs to move from IND to BLA. They also track the economics behind production, from GMP compliance costs to continuous manufacturing gains. Across regions and therapy types, investment patterns, development costs, and pricing dynamics—like biosimilar discounts—help explain where growth is likely and why speed and risk matter.
Key Takeaways
- $307.3 billion global bioeconomy market size in 2022
- $1.6 trillion global pharmaceutical industry market size in 2023
- 13.3% CAGR for the global biopharmaceuticals market from 2024 to 2032
- 32.5% of global biopharma funding in 2023 came from late-stage deals
- 11% year-over-year decline in global biopharma funding in 2023 vs. 2022
- 6.7% share of global R&D spending by biopharma in 2022 (sector-level estimate)
- 4.4 years median time from IND to BLA approval for oncology drugs approved in 2015–2020
- 9.6% of investigational drugs entering clinical trials reached market approval (success rate)
- 1.6% average annual compliance cost increase for GMP manufacturing operations in the U.S. (2019–2022)
- $2.8 billion average cost to develop a new drug (including failures)
- $54.0 million average cost to conduct a Phase III trial (median, 2021 USD)
- 20% reduction in unit manufacturing cost achievable with continuous manufacturing (modeled ranges)
- $3.7 billion U.S. NIH funding for biotechnology research in FY 2022
- 4,300+ bio-based industry establishments in the U.S. (NAICS 3118–3254, 2017)
- 1,905 bioeconomy companies located in the EU (2022)
With soaring biopharma growth and rising R and D costs, biotech markets reached $307.3B in 2022.
Related reading
01 · Category
Market Size11 stats
01
$307.3 billion global bioeconomy market size in 2022
02
$1.6 trillion global pharmaceutical industry market size in 2023
03
13.3% CAGR for the global biopharmaceuticals market from 2024 to 2032
04
$9.8 billion global market for lab automation in 2023
05
$21.4 billion global CDMO market size in 2023
06
$2,8 trillion global pharmaceuticals market size in 2023
07
$21.4 billion global CDMO market size in 2023
08
$9.8 billion global lab automation market size in 2023
09
$307.3 billion global bioeconomy market size in 2022
10
$0.0 billion global biopharmaceuticals market size in 2023
11
$0.0 billion global biopharmaceuticals market size in 2032
Interpretation
Market Size Interpretation
The market size data shows rapid expansion across the bio sector, with the global bioeconomy reaching $307.3 billion in 2022 and biopharmaceuticals projected to grow at a 13.3% CAGR from 2024 to 2032, alongside major adjacent opportunity pools like a $21.4 billion CDMO market in 2023 and a $9.8 billion lab automation market in 2023.
report visual · Comparison
Global bio-industry market size (2022–2023)
Across the provided bio-industry market-size estimates, pharmaceuticals (2023) is the clear leader, with the largest global value, substantially outpacing the smaller sub-markets (
$2,8 trillion global pharmaceuticals market size in 2023$1,600 billion
$307.3 billion global bioeconomy market size in 2022$307.3 billion
$21.4 billion global CDMO market size in 2023$21.4 billion
$9.8 billion global lab automation market size in 2023$9.8 billion
source-verifiedomdia.tech.informa.com · grandviewresearch.com · globenewswire.com2023
02 · Category
Industry Trends3 stats
01
32.5% of global biopharma funding in 2023 came from late-stage deals
02
11% year-over-year decline in global biopharma funding in 2023 vs. 2022
03
6.7% share of global R&D spending by biopharma in 2022 (sector-level estimate)
Interpretation
Industry Trends Interpretation
In 2023, despite a 11% year-over-year decline in global biopharma funding, late-stage deals still accounted for 32.5% of total funding, signaling an industry trend toward prioritizing later-stage opportunities rather than broad early investment.
03 · Category
Performance Metrics4 stats
01
4.4 years median time from IND to BLA approval for oncology drugs approved in 2015–2020
02
9.6% of investigational drugs entering clinical trials reached market approval (success rate)
03
1.6% average annual compliance cost increase for GMP manufacturing operations in the U.S. (2019–2022)
04
Median overall survival improvement of 6.7 months for CAR-T therapies across pivotal studies (range)
Interpretation
Performance Metrics Interpretation
From the Performance Metrics perspective, oncology drugs still take a median of 4.4 years from IND to BLA approval and only 9.6% of investigational drugs reach market, yet major therapies like CAR T show a measurable payoff with a median overall survival gain of 6.7 months across pivotal studies.
More related reading
04 · Category
Cost Analysis6 stats
01
$2.8 billion average cost to develop a new drug (including failures)
02
$54.0 million average cost to conduct a Phase III trial (median, 2021 USD)
03
20% reduction in unit manufacturing cost achievable with continuous manufacturing (modeled ranges)
04
15–25% price reductions for biosimilars compared with reference biologics (within EU markets)
05
3.0x faster manufacturing lead times possible with single-use bioprocessing (industry benchmarks)
06
25% lower facility CAPEX requirement for single-use systems vs. stainless steel (modeling estimate)
Interpretation
Cost Analysis Interpretation
Cost pressures and opportunities across drug development and biologics production are significant, with new drugs averaging $2.8 billion and Phase III trials costing about $54.0 million, while manufacturing approaches like continuous and single use can cut costs and timelines through a modeled 20% unit manufacturing reduction and up to 3.0x faster lead times.
05 · Category
Bioeconomy Scope4 stats
01
$3.7 billion U.S. NIH funding for biotechnology research in FY 2022
02
4,300+ bio-based industry establishments in the U.S. (NAICS 3118–3254, 2017)
03
1,905 bioeconomy companies located in the EU (2022)
04
29.4% of global manufacturing sites in pharma/biotech are in North America (2023)
Interpretation
Bioeconomy Scope Interpretation
Within the Bioeconomy Scope, the sector’s momentum is clear as the U.S. invested $3.7 billion in NIH biotechnology research in FY 2022 and hosts 4,300+ bio-based industry establishments, while Europe adds 1,905 bioeconomy companies and North America accounts for 29.4% of global pharma and biotech manufacturing sites.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Bio Industry Statistics. Gitnux. https://gitnux.org/bio-industry-statistics
MLA
Catherine Wu. "Bio Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/bio-industry-statistics.
Chicago
Catherine Wu. 2026. "Bio Industry Statistics." Gitnux. https://gitnux.org/bio-industry-statistics.
Sources & references
27 datasets cited across this report · attribution is report-level
+7 additional datasets cited (not shown individually)